What it is
TB-500 is LKKTETQ, a chain of seven amino acids (each letter stands for one), and a short piece of a larger protein called thymosin beta-4. It isn't the whole protein, so studies of the whole protein in people can't be assumed to apply to TB-500.
What makes it distinct
The mix-up is the story. There are studies of whole thymosin beta-4 in people. They're studies of a different molecule, and human studies haven't proven they apply to TB-500. Our sources record that the FDA found no data on people taking drug products that contain this fragment. It also says compounded TB-500 (mixed from its ingredients by a pharmacist or doctor) given certain ways may carry a risk of immune reactions (immunogenicity), because of the potential for the peptide to clump together (aggregation) and for impurities related to it.
Open questions
- Whether results for whole thymosin beta-4 tell us anything about the fragment. Human studies haven't proven that they do.
- How long it lasts in the body (pharmacokinetics). We found no measured half-life (the time it takes for half a dose to clear) for TB-500 in people. Tidepath doesn't chart its levels.
Worth knowing
If something you read about TB-500 cites thymosin beta-4 research without telling the two apart, that's worth noticing. It's how one molecule borrows another's evidence.
More in Repair and recovery peptides